Key result
Cardiogenic shock or preshock is linked to ~35% 30-day all-cause mortality across SCAI stages B-E.
Cohort (n=471)
Yes
The ongoing MIRACLE multicenter cohort study demonstrates the feasibility of serial SCAI staging, repeated biobanking, and 6-month survivor assessments in cardiogenic shock across etiologies, showing an interim overall 30-day mortality of 35%.
Answers are grounded in this paper and cite their sources.
Multimodal phenotyping may refine cardiogenic shock risk stratification beyond AMI; leaves open prospective validation across etiologies before practice change.
RATIONALE: Cardiogenic shock carries high mortality, yet most evidence comes from patients with shock related to acute myocardial infarction. Cohorts that combine serial staging, repeated biobanking, and structured assessment of survivors across severity stages and etiologies are scarce. OBJECTIVE: MIRACLE (multimodal phenotyping in patients referred with acute cardiac failure) aims at multimodal phenotyping and risk stratification of patients with cardiogenic shock across etiologies. The primary endpoint is all-cause mortality at 30 days. DESIGN: Prospective, observational, multicenter cohort study with an embedded biobank. Adults with Society for Cardiovascular Angiography and Interventions (SCAI) stage B preshock or stage C to E shock of any etiology are enrolled in intensive and intermediate care units. Patients with a large anterior ST-elevation myocardial infarction without shock are enrolled as controls (SCAI A) for shock related to myocardial infarction. SCAI stages are reassessed during the first 24 hours after admission to intensive care and at study visits on days 1, 3, and 5 and at discharge from intensive care, each with biobanking. Follow-up extends to 12 months and includes a visit at 6 months with repeat biobanking, exercise testing, cognitive assessment, and patient-reported outcomes. SITES: Four centers in Germany. ESTIMATED ENROLLMENT: Approximately 600 patients, ≥ 500 day-1 samples. ENROLLMENT DATES: August 2024 to the middle of 2027 (estimated). CURRENT STATUS: As of 30 September 2026, 449 patients with shock or preshock and 22 controls had been enrolled. Blood samples on day 1 were obtained in 88% of eligible patients, and follow-up at 6 months was completed in 86% of eligible survivors, at the study site in 148 and by telephone in 62. Mortality at 30 days was 15% in SCAI stage B and 63% in stage E (overall 35%). Enrollment is limited to German academic centers, and very early deaths may have been missed. TRIAL REGISTRATION: ClinicalTrials.gov, NCT07515508, https://clinicaltrials.gov/study/NCT07515508.
No takes yet. Share an insight, caveat, or question.
Heidenreich et al. (2026) conducted a cohort in Cardiogenic shock and preshock (SCAI stages B to E) (n=471). Cardiogenic shock or preshock across SCAI stages B to E with serial multimodal phenotyping and biobanking vs. Large anterior ST-elevation myocardial infarction without shock (SCAI stage A) was evaluated on All-cause mortality at 30 days. Cardiogenic shock or preshock (SCAI stages B-E) was associated with an overall 30-day all-cause mortality of 35%.
Synapse has enriched 10 related papers. Consider them for comparative context: